FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075492062> ?p ?o ?g. }

• W2075492062 endingPage "3307" @default.
• W2075492062 startingPage "3295" @default.
• W2075492062 abstract "The 5-aziridinyl-2,4-dinitrobenzamide CB 1954 is a substrate for the oxygen-insensitive nitroreductase (NTR) from E. coli and is in clinical trial in combination with NTR-armed adenoviral vectors in a GDEPT protocol; CB 1954 is also of interest for selective deletion of NTR-marked cells in normal tissues. Since little further drug development has been carried out around this lead, we report here the synthesis of more soluble variants and regioisomers and structure-activity relationship (SAR) studies. The compounds were primarily prepared from the corresponding chloro(di)nitroacids through amide side chain elaboration and subsequent aziridine formation. One-electron reduction potentials [E(1)], determined by pulse radiolysis, were around -400 mV, varying little for aziridinyldinitrobenzamide regioisomers. Cytotoxicity in a panel of NTR-transfected cell lines showed that in the CB 1954 series there was considerable tolerance of substituted CONHR side chains. The isomeric 2-aziridinyl-3,5-dinitrobenzamide was also selective toward NTR+ve lines but was approximately 10-fold less potent than CB 1954. Other regioisomers were too insoluble to evaluate. While CB 1954 gave both 2- and 4-hydroxylamine metabolites in NTR+ve cells, related analogues with substituted carboxamides gave only a single hydroxylamine metabolite possibly because the steric bulk in the side chain constrains binding within the active site. CB 1954 is also a substrate for the two-electron reductase DT-diaphorase, but all of the other aziridines (regioisomers and close analogues) were poorer substrates with resulting improved specificity for NTR. Bystander effects were determined in multicellular layer cocultures and showed that the more hydrophilic side chains resulted in a modest reduction in bystander killing efficiency. A limited number of analogues were tested for in vivo activity, using a single ip dose to CD-1 nude mice bearing WiDr-NTR(neo) tumors. The most active of the CB 1954 analogues was a diol derivative, which showed a substantial median tumor growth delay (59 days compared with >85 days for CB 1954) in WiDr xenografts comprising 50% NTR+ve cells. The diol is much more soluble and can be formulated in saline for administration. The results suggest there may be advantages with carefully selected analogues of CB 1954; the weaker bystander effect of its diol derivative may be an advantage in the selective cell ablation of NTR-tagged cells in normal tissues." @default.
• W2075492062 created "2016-06-24" @default.
• W2075492062 creator A5002482765 @default.
• W2075492062 creator A5013672310 @default.
• W2075492062 creator A5018869767 @default.
• W2075492062 creator A5023901201 @default.
• W2075492062 creator A5079557293 @default.
• W2075492062 creator A5087508568 @default.
• W2075492062 creator A5090098921 @default.
• W2075492062 creator A5090181111 @default.
• W2075492062 creator A5091278547 @default.
• W2075492062 creator A5073341324 @default.
• W2075492062 date "2004-05-12" @default.
• W2075492062 modified "2023-09-23" @default.
• W2075492062 title "Aziridinyldinitrobenzamides: Synthesis and Structure−Activity Relationships for Activation by <i>E. </i><i>coli</i> Nitroreductase" @default.
• W2075492062 cites W1489452981 @default.
• W2075492062 cites W1966538775 @default.
• W2075492062 cites W1972305370 @default.
• W2075492062 cites W1978222385 @default.
• W2075492062 cites W1980113061 @default.
• W2075492062 cites W1981342262 @default.
• W2075492062 cites W1984539540 @default.
• W2075492062 cites W1987854627 @default.
• W2075492062 cites W1988938382 @default.
• W2075492062 cites W1994819259 @default.
• W2075492062 cites W2003215891 @default.
• W2075492062 cites W2012616137 @default.
• W2075492062 cites W2017319763 @default.
• W2075492062 cites W2017382169 @default.
• W2075492062 cites W2017536393 @default.
• W2075492062 cites W2023420364 @default.
• W2075492062 cites W2038930381 @default.
• W2075492062 cites W2047955219 @default.
• W2075492062 cites W2052343242 @default.
• W2075492062 cites W2062444423 @default.
• W2075492062 cites W2064457654 @default.
• W2075492062 cites W2074067031 @default.
• W2075492062 cites W2083594139 @default.
• W2075492062 cites W2083641287 @default.
• W2075492062 cites W2088574698 @default.
• W2075492062 cites W2103673388 @default.
• W2075492062 cites W2109689528 @default.
• W2075492062 cites W2134986127 @default.
• W2075492062 cites W2138533612 @default.
• W2075492062 cites W2140792027 @default.
• W2075492062 cites W2149944899 @default.
• W2075492062 cites W2313370831 @default.
• W2075492062 cites W2325259865 @default.
• W2075492062 cites W2411626078 @default.
• W2075492062 doi "https://doi.org/10.1021/jm0498699" @default.
• W2075492062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15163209" @default.
• W2075492062 hasPublicationYear "2004" @default.
• W2075492062 type Work @default.
• W2075492062 sameAs 2075492062 @default.
• W2075492062 citedByCount "30" @default.
• W2075492062 countsByYear W20754920622012 @default.
• W2075492062 countsByYear W20754920622014 @default.
• W2075492062 countsByYear W20754920622015 @default.
• W2075492062 countsByYear W20754920622016 @default.
• W2075492062 countsByYear W20754920622017 @default.
• W2075492062 countsByYear W20754920622018 @default.
• W2075492062 countsByYear W20754920622020 @default.
• W2075492062 countsByYear W20754920622021 @default.
• W2075492062 countsByYear W20754920622022 @default.
• W2075492062 crossrefType "journal-article" @default.
• W2075492062 hasAuthorship W2075492062A5002482765 @default.
• W2075492062 hasAuthorship W2075492062A5013672310 @default.
• W2075492062 hasAuthorship W2075492062A5018869767 @default.
• W2075492062 hasAuthorship W2075492062A5023901201 @default.
• W2075492062 hasAuthorship W2075492062A5073341324 @default.
• W2075492062 hasAuthorship W2075492062A5079557293 @default.
• W2075492062 hasAuthorship W2075492062A5087508568 @default.
• W2075492062 hasAuthorship W2075492062A5090098921 @default.
• W2075492062 hasAuthorship W2075492062A5090181111 @default.
• W2075492062 hasAuthorship W2075492062A5091278547 @default.
• W2075492062 hasConcept C108215921 @default.
• W2075492062 hasConcept C109316439 @default.
• W2075492062 hasConcept C185592680 @default.
• W2075492062 hasConcept C193042331 @default.
• W2075492062 hasConcept C201399114 @default.
• W2075492062 hasConcept C202235601 @default.
• W2075492062 hasConcept C202751555 @default.
• W2075492062 hasConcept C2775999725 @default.
• W2075492062 hasConcept C2776313096 @default.
• W2075492062 hasConcept C2777477808 @default.
• W2075492062 hasConcept C2781326480 @default.
• W2075492062 hasConcept C55493867 @default.
• W2075492062 hasConcept C71240020 @default.
• W2075492062 hasConceptScore W2075492062C108215921 @default.
• W2075492062 hasConceptScore W2075492062C109316439 @default.
• W2075492062 hasConceptScore W2075492062C185592680 @default.
• W2075492062 hasConceptScore W2075492062C193042331 @default.
• W2075492062 hasConceptScore W2075492062C201399114 @default.
• W2075492062 hasConceptScore W2075492062C202235601 @default.
• W2075492062 hasConceptScore W2075492062C202751555 @default.
• W2075492062 hasConceptScore W2075492062C2775999725 @default.
• W2075492062 hasConceptScore W2075492062C2776313096 @default.
• W2075492062 hasConceptScore W2075492062C2777477808 @default.

• next